Valuation : Ligand Pharmaceuticals Incorporated

Market Cap 5.74B 4.94B 4.65B 4.24B 7.93B 546B 7.96B 55.14B 21.31B 278B 21.56B 21.09B 882B P/E 2026 *
55x
P/E 2027 * 33.7x
Enterprise Value 5.74B 4.94B 4.65B 4.24B 7.93B 546B 7.96B 55.14B 21.31B 278B 21.56B 21.09B 882B EV / Sales 2026 *
19.8x
EV / Sales 2027 * 15.1x
Free-Float
97.62%
Yield 2026 *
-
Yield 2027 * -
1 day-0.27%
1 week+0.39%
Current month+1.39%
1 month-1.74%
3 months+18.40%
6 months+38.38%
Current year+52.35%
1 week 278.4
Extreme 278.3953
291.82
1 month 275.6
Extreme 275.6
299.34
Current year 175.89
Extreme 175.89
326.63
1 year 161.82
Extreme 161.82
326.63
3 years 49.24
Extreme 49.24
326.63
5 years 49.24
Extreme 49.24
326.63
10 years 49.24
Extreme 49.24
326.63
Manager TitleAgeSince
Chief Executive Officer 65 2022-12-04
Director of Finance/CFO 47 2015-05-20
Director of Finance/CFO 56 2022-10-31
Director TitleAgeSince
Chairman 76 2003-02-28
Director/Board Member 57 2006-09-26
Director/Board Member 65 2007-02-28
Date Insider Type Main position Quantity % Market Cap. Importance
8/12/26 Exercice

Chief Financial Officer

94,923 0.4736%
8/12/26 Exercice

Director

19,414 0.0969%
8/3/26 Exercice

General Counsel

15,000 0.0748%
Change 5-day change 1-year change 3-year change Capi.($)
-0.27%+0.39%+74.15%+356.86% 5.74B
+0.03%-3.09%+49.77%+91.69% 1,002B
-0.76%-2.95%+50.93%+66.34% 644B
+0.86%-4.13%+19.24%+68.37% 443B
-0.80%-0.43%+28.92%+35.45% 343B
-0.13%-14.97%+9.41%+26.71% 262B
-1.90%-2.72%-2.72%+7.41% 245B
-0.48%-11.65%+39.75%+50.82% 212B
-1.06%-4.23%-14.70%-57.36% 199B
-0.68%-2.65%+25.82%+91.64% 181B
Average -0.54%-3.94%+28.06%+73.79% 353.54B
Weighted average by Cap. -0.42%-3.88%+32.10%+57.65%

Financials

2026 *2027 *
Net sales 290M 249M 235M 214M 400M 27.58B 402M 2.78B 1.08B 14.05B 1.09B 1.06B 44.51B 381M 327M 308M 281M 526M 36.21B 528M 3.65B 1.41B 18.45B 1.43B 1.4B 58.44B
Net income 112M 96.24M 90.62M 82.57M 154M 10.64B 155M 1.07B 415M 5.42B 420M 411M 17.18B 187M 161M 151M 138M 258M 17.78B 259M 1.79B 694M 9.06B 702M 687M 28.7B
Net Debt - -
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.
Employees
47
Date Price Change Volume
26-09-09 US$288.05 -0.27% 309,964
26-09-08 US$288.83 +1.13% 216,423
26-09-04 US$285.60 -1.43% 132,389
26-09-03 US$289.74 +0.98% 190,728
26-09-02 US$286.92 +0.93% 189,615
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
288.05USD
Average target price
342.82USD
Spread / Average Target
+19.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LGND Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!